159938 医药
已收盘 02-12 15:00:00
资讯
新帖
简况
新股前瞻|局部递送靶向疗法领导者，普祺医药能否撑起24亿估值？
智通财经 · 18:29
新股前瞻|局部递送靶向疗法领导者，普祺医药能否撑起24亿估值？
同源康医药-B(02410)：联交所就实施H股全流通授出上市批准
智通财经 · 17:07
同源康医药-B(02410)：联交所就实施H股全流通授出上市批准
2月12日爱迪特涨15.44%，银河医药混合A基金重仓该股
证券之星 · 16:42
2月12日爱迪特涨15.44%，银河医药混合A基金重仓该股
2月12日常山药业跌6.11%，医药LOF基金重仓该股
证券之星 · 16:40
2月12日常山药业跌6.11%，医药LOF基金重仓该股
【新股IPO】博纳西亚(杭州)医药科技股份有限公司向港交所主板提交上市申请
金吾财讯 · 02-11 23:40
【新股IPO】博纳西亚(杭州)医药科技股份有限公司向港交所主板提交上市申请
和誉医药FGFR4抑制剂依帕戈替尼完成全球多中心I期临床扩展阶段美国首例患者给药
经济参考网 · 02-11 14:30
和誉医药FGFR4抑制剂依帕戈替尼完成全球多中心I期临床扩展阶段美国首例患者给药
一品红：公司始终坚持医药创新和高品质药品研发
证券之星 · 02-11 08:54
一品红：公司始终坚持医药创新和高品质药品研发
1至8批国家集采药品接续采购开标；阿斯利康去年全球总营收达587.39亿美元丨医药早参
每日经济新闻 · 02-11 07:08
1至8批国家集采药品接续采购开标；阿斯利康去年全球总营收达587.39亿美元丨医药早参
国泰海通｜医药：医疗设备招采规模高基数影响部分回落，关注手术机器人市场机遇
国泰君安证券研究 · 02-10 22:00
国泰海通｜医药：医疗设备招采规模高基数影响部分回落，关注手术机器人市场机遇
西陇科学：公司产品包含医用原料药及药用辅料、医药中间体等产品
证券之星 · 02-10 20:52
西陇科学：公司产品包含医用原料药及药用辅料、医药中间体等产品
欧康医药发布2025年度业绩快报，盈利0.116亿元
证券之星 · 02-10 18:10
欧康医药发布2025年度业绩快报，盈利0.116亿元
爱迪特：富国基金、国联民生医药等多家机构于2月9日调研我司
中金财经 · 02-10 10:30
爱迪特：富国基金、国联民生医药等多家机构于2月9日调研我司
恒生医疗保健指数升2.17% 医药板块普遍拉升 机构持续看好中国创新药出海的产业趋势
金吾财讯 · 02-10 09:59
恒生医疗保健指数升2.17% 医药板块普遍拉升 机构持续看好中国创新药出海的产业趋势
“惠民保”最大服务商再冲港股IPO！镁信健康半年两递表，12亿亏损下医药支付赛道迎考
时代财经 · 02-10 08:22
“惠民保”最大服务商再冲港股IPO！镁信健康半年两递表，12亿亏损下医药支付赛道迎考
劲方医药-B(02595.HK)：取消监事会
中金财经 · 02-09
劲方医药-B(02595.HK)：取消监事会
2月9日三博脑科涨5.32%，银河医药混合A基金重仓该股
证券之星 · 02-09
2月9日三博脑科涨5.32%，银河医药混合A基金重仓该股
华昊中天医药-B：中国证监会就公司股份全流通发出备案通知书
新浪港股 · 02-09
华昊中天医药-B：中国证监会就公司股份全流通发出备案通知书
丹诺医药拿到IPO备案：暂无收入，9个月亏1.15亿 估值20亿
雷递网 · 02-08
丹诺医药拿到IPO备案：暂无收入，9个月亏1.15亿 估值20亿
六大领域齐发力 青海中（藏）医药为健康青海添动能
西海都市报 · 02-07
六大领域齐发力 青海中（藏）医药为健康青海添动能
华昊中天医药-B(02563)：中国证监会就公司股份全流通发出备案通知书
智通财经 · 02-06
华昊中天医药-B(02563)：中国证监会就公司股份全流通发出备案通知书
加载更多
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159938","market":"SZ","secType":"STK","nameCN":"医药","latestPrice":0.665,"timestamp":1770879813000,"preClose":0.667,"halted":0,"volume":22697800,"delay":0,"changeRate":-0.003,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-0.002,"latestTime":"02-12 15:00:00","open":0.668,"high":0.672,"low":0.665,"amount":15132100,"amplitude":0.0105,"askPrice":0.666,"askSize":1436,"bidPrice":0.665,"bidSize":3224,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770946200000},"marketStatusCode":5,"adr":0,"adjPreClose":0.667,"symbolType":"fund","openAndCloseTimeList":[[1770859800000,1770867000000],[1770872400000,1770879600000]],"highLimit":0.734,"lowLimit":0.6,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":-0.186652,"marketValue":0,"turnoverRate":0,"status":1,"floatMarketCap":0},"requestUrl":"/m/hq/s/159938","defaultTab":"news","newsList":[{"id":"2610993944","title":"新股前瞻|局部递送靶向疗法领导者，普祺医药能否撑起24亿估值？","url":"https://stock-news.laohu8.com/highlight/detail?id=2610993944","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610993944?lang=zh_cn&edition=full","pubTime":"2026-02-12 18:29","pubTimestamp":1770892157,"startTime":"0","endTime":"0","summary":"招股书显示，普祺医药专注于免疫炎症领域，定位“局部递送靶向疗法的领导者”。公司成立于2016年，以创新设计和局部递送为核心技术平台，深耕特应性皮炎、过敏性鼻炎等慢性炎症疾病。截至2025年9月，普祺医药现金及现金等价物仅1.55亿元，紧张的资金状况，凸显了公司寻求上市融资的紧迫性。这意味着，在未来3至5年内，普祺医药大概率仍需高度依赖核心产品普美昔替尼支撑估值与现金流，后续管线短期内难以形成实质性的业绩接力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404758.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09939","BK1515","BK1161","159938"],"gpt_icon":0},{"id":"2610945167","title":"同源康医药-B(02410)：联交所就实施H股全流通授出上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2610945167","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610945167?lang=zh_cn&edition=full","pubTime":"2026-02-12 17:07","pubTimestamp":1770887224,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同源康医药-B(02410)公布，公司已向联交所上市委员会申请批准公司根据转换公司1名股东持有的460.8万股非上市股份转换的460.8万股H股上市及买卖经转换H股。联交所已于2026年2月11日授出上市批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404690.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","02410","09939","BK1515","159938"],"gpt_icon":0},{"id":"2610694360","title":"2月12日爱迪特涨15.44%，银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2610694360","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610694360?lang=zh_cn&edition=full","pubTime":"2026-02-12 16:42","pubTimestamp":1770885754,"startTime":"0","endTime":"0","summary":"证券之星消息，2月12日爱迪特涨15.44%创60日新高，收盘报63.7元，换手率14.24%，成交量10.25万手，成交额6.23亿元。重仓爱迪特的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为银河基金的银河医药混合A。银河医药混合A目前规模为4.29亿元，最新净值0.611，较上一交易日下跌0.15%，近一年上涨20.42%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021200026498.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","159938","09939","BK0251","BK1574","301580","BK1515"],"gpt_icon":0},{"id":"2610439789","title":"2月12日常山药业跌6.11%，医药LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2610439789","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610439789?lang=zh_cn&edition=full","pubTime":"2026-02-12 16:40","pubTimestamp":1770885605,"startTime":"0","endTime":"0","summary":"证券之星消息，2月12日常山药业跌6.11%创60日新低，收盘报43.49元，换手率4.08%，成交量37.43万手，成交额16.43亿元。重仓常山药业的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为国泰基金的医药LOF。医药LOF目前规模为6.54亿元，最新净值0.5775，较上一交易日下跌0.05%，近一年上涨9.56%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021200026421.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","09939","BK0070","300255","BK0239","159938","BK1515","BK0172"],"gpt_icon":0},{"id":"2610511969","title":"【新股IPO】博纳西亚(杭州)医药科技股份有限公司向港交所主板提交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2610511969","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610511969?lang=zh_cn&edition=full","pubTime":"2026-02-11 23:40","pubTimestamp":1770824400,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所2月11日披露，博纳西亚 医药科技股份有限公司向港交所主板提交上市申请，兴证国际、工银国际为其联席保荐人。公司是一家总部位于中国杭州的临床合同研究组织机构，致力于通过数字化赋能创新药临床研究。公司的核心业务是为国内外制药及生物技术公司提供临床试验技术服务，旨在加速化学药物和生物制品的研发及商业化进程。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/Nzc3MzgwMzMzMzM4NGQyNThhOGYxYzk1ZjFmM2VmN2U1NDI1NjgyMzc0Ng==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/Nzc3MzgwMzMzMzM4NGQyNThhOGYxYzk1ZjFmM2VmN2U1NDI1NjgyMzc0Ng==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1974990","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","HEXmain","09939","BK1515","159938"],"gpt_icon":0},{"id":"2610164983","title":"和誉医药FGFR4抑制剂依帕戈替尼完成全球多中心I期临床扩展阶段美国首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2610164983","media":"经济参考网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610164983?lang=zh_cn&edition=full","pubTime":"2026-02-11 14:30","pubTimestamp":1770791400,"startTime":"0","endTime":"0","summary":"2月11日，上海和誉生物医药科技有限公司(以下简称“和誉医药”，港交所代码：02256)今日宣布，其自主研发的高选择性小分子FGFR4抑制剂依帕戈替尼(Irpagratinib/ABSK-011)针对FGF19过表达晚 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260211/c674725049.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159938"],"gpt_icon":0},{"id":"2610036826","title":"一品红：公司始终坚持医药创新和高品质药品研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2610036826","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610036826?lang=zh_cn&edition=full","pubTime":"2026-02-11 08:54","pubTimestamp":1770771251,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红(300723)02月10日在投资者关系平台上答复投资者关心的问题。投资者提问：请问第一季度出售疼风药股权，只占15%左右的股份也就是10亿人民币的资金到账，是否为了应对之前的五亿诉讼一品红回复：尊敬的投资者您好，感谢您对公司的关注。一品红是一家集药品研发、生产、销售为一体的创新型生物医药企业，聚焦于儿童药和慢病药领域。公司始终坚持医药创新和高品质药品研发。祝您投资愉快。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021100005980.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","09939","BK0239","BK1574","BK1161","BK1515","300723"],"gpt_icon":0},{"id":"2610677847","title":"1至8批国家集采药品接续采购开标；阿斯利康去年全球总营收达587.39亿美元丨医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2610677847","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610677847?lang=zh_cn&edition=full","pubTime":"2026-02-11 07:08","pubTimestamp":1770764904,"startTime":"0","endTime":"0","summary":"丨2026年2月11日星期三丨NO.11至8批国家集采药品接续采购开标据央视新闻2月10日报道，记者从国家医保局获悉，1至8批国家集采药品新一轮接续采购开标产生拟中选结果，涉及316种常用药品，1020家企业的4163个产品获得拟中选资格。本次接续采购的药品覆盖抗感染、抗肿瘤、降血糖、降血压、降血脂、神经系统、呼吸系统、消化系统等26个治疗领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602113647093451.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602113647093451.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159938","09939","AZN"],"gpt_icon":0},{"id":"2610673599","title":"国泰海通｜医药：医疗设备招采规模高基数影响部分回落，关注手术机器人市场机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2610673599","media":"国泰君安证券研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610673599?lang=zh_cn&edition=full","pubTime":"2026-02-10 22:00","pubTimestamp":1770732000,"startTime":"0","endTime":"0","summary":"手术机器人服务价格项目立项指南发布，渗透率加速提升。设备招采复苏不及预期，政策落地不及预期，产品价格波动风险等。报告名称：医疗设备招采规模高基数影响部分回落，关注手术机器人市场机遇；报告日期：2026.02.09 报告作者：江珅（分析师），登记编号：S0880525090001赵峻峰（分析师），登记编号：S0880519080017余文心（分析师），登记编号：S0880525040111重要提醒本订阅号所载内容仅面向国泰海通证券研究服务签约客户。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MzEwMDEzNQ==&mid=2650536537&idx=4&sn=61459e8b2d443bb890244d22ce1cdae9&chksm=89f91a2bb4319552c2ef11d84d97615781f75e5c54a8fc3510e7602460e21016cdfe48a30aa8&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1161","BK1515","BK1147","09939","02611","BK0184","BK1574","601211","BK0012","BK0188","BK0276","BK1564","BK0183","BK0028","159938","BK0201","159873"],"gpt_icon":0},{"id":"2610640118","title":"西陇科学：公司产品包含医用原料药及药用辅料、医药中间体等产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2610640118","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610640118?lang=zh_cn&edition=full","pubTime":"2026-02-10 20:52","pubTimestamp":1770727928,"startTime":"0","endTime":"0","summary":"证券之星消息，西陇科学(002584)02月09日在投资者关系平台上答复投资者关心的问题。投资者提问：公司在生物制药方面有合作么西陇科学回复：投资者你好，公司产品主要应用领域包括生物医药，公司目前生产的产品包含医用原料药及药用辅料、医药中间体等产品，感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000036821.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","159938","002584","BK0070","BK1161","BK1515","BK0042","BK0077","BK1574","BK0229"],"gpt_icon":0},{"id":"2610164598","title":"欧康医药发布2025年度业绩快报，盈利0.116亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610164598","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610164598?lang=zh_cn&edition=full","pubTime":"2026-02-10 18:10","pubTimestamp":1770718238,"startTime":"0","endTime":"0","summary":"证券之星消息，欧康医药近日即将发布2025年年报，根据2月10日发布的业绩快报，归属净利润盈利0.116亿元，同比减少48.21%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000029569.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","159938","BK1161","BK1515","BK1574"],"gpt_icon":0},{"id":"2610998136","title":"爱迪特：富国基金、国联民生医药等多家机构于2月9日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2610998136","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610998136?lang=zh_cn&edition=full","pubTime":"2026-02-10 10:30","pubTimestamp":1770690604,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年2月10日爱迪特发布公告称富国基金、国联民生医药于2026年2月9日调研我司。 问：请公司介绍一下 2025 年经营情况和发展成果？ 答：公司 2025 年整体营收增长节奏与前三季度基本一致，盈利端实现较好增长，利润增速高于收入增速。 公司四季度及全年具体经营数据，将以公司后续披露的年度报告为准。 爱迪特主营业务：口腔修复材料的研发、生产和销售;口腔数字化设备的设计和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260210/32009213.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["159938","301580","BK1564","BK1147","BK1515","BK1574","BK1161","09939","BK0251","BK0276","601456","01456"],"gpt_icon":0},{"id":"2610268695","title":"恒生医疗保健指数升2.17% 医药板块普遍拉升 机构持续看好中国创新药出海的产业趋势","url":"https://stock-news.laohu8.com/highlight/detail?id=2610268695","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610268695?lang=zh_cn&edition=full","pubTime":"2026-02-10 09:59","pubTimestamp":1770688793,"startTime":"0","endTime":"0","summary":"2月8日，信达生物宣布与礼来制药达成战略合作，携手推进肿瘤及免疫领域创新药物的全球研发。2026年，继续看好中国创新药出海的产业趋势，继续重点跟踪ADC、双抗、小核酸、减肥药等核心优势赛道的投资机会，期待JPM大会、ASCO等带来数据更新和BD催化。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8f73ea90e21e93e4b02cf2f8986a9c30","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1974845","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359","159506","LU1688375341.USD","LU0051755006.USD","LU0196878994.USD","159938","09926","02268","LU1046422090.SGD","LU0417516902.SGD","09969","01877","LU0516422366.SGD","LU1961090484.USD","01801","09939","06978","HK0000306701.USD","LU0043850808.USD","LU0634319403.HKD","LU0359202008.SGD","03347","LU0417516738.SGD","02162","BK1587","LU0348825331.USD","159992","LU0572944931.SGD","LU0140636845.USD","BK1161","LU1969619763.USD","LU0823426308.USD","01548","LU2476274720.SGD","02696","LU1720050803.USD","LU2039709279.SGD","LU0181495838.USD","LU2242644610.SGD","06990","LU2476274308.USD","IE00B5MMRT66.SGD","LU2488822045.USD","09688","LU2045819591.USD","LU0516423174.USD","09995","02269","LU0856984785.SGD","LU0502904849.HKD"],"gpt_icon":1},{"id":"2610660171","title":"“惠民保”最大服务商再冲港股IPO！镁信健康半年两递表，12亿亏损下医药支付赛道迎考","url":"https://stock-news.laohu8.com/highlight/detail?id=2610660171","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610660171?lang=zh_cn&edition=full","pubTime":"2026-02-10 08:22","pubTimestamp":1770682920,"startTime":"0","endTime":"0","summary":"近日，惠民保的最大综合服务提供商再次冲刺港股IPO。1月16日，上海镁信健康科技集团股份有限公司（下称“镁信健康”）再度向港交所递交主板上市申请，高盛（亚洲）、中金公司、汇丰银行等三 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260210/c674681057.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["159938"],"gpt_icon":0},{"id":"2610659714","title":"劲方医药-B(02595.HK)：取消监事会","url":"https://stock-news.laohu8.com/highlight/detail?id=2610659714","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610659714?lang=zh_cn&edition=full","pubTime":"2026-02-09 22:47","pubTimestamp":1770648421,"startTime":"0","endTime":"0","summary":"格隆汇2月9日丨劲方医药-B(02595.HK)公告，股东于股东特别大会上通过特别决议案以批准取消监事会及修订组织章程细则。因此，自2026年2月9日起，公司将不再设有监事会，现任监事会成员不再担任监事；及经修订组织章程细则将自股东特别大会当日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260209/32008546.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","159938","09939","BK1515","BK1161","02595"],"gpt_icon":0},{"id":"2610680040","title":"2月9日三博脑科涨5.32%，银河医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2610680040","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610680040?lang=zh_cn&edition=full","pubTime":"2026-02-09 16:41","pubTimestamp":1770626484,"startTime":"0","endTime":"0","summary":"证券之星消息，2月9日三博脑科涨5.32%，收盘报77.19元，换手率9.05%，成交量14.56万手，成交额11.12亿元。重仓三博脑科的公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为银河基金的银河医药混合A。银河医药混合A目前规模为4.29亿元，最新净值0.6071，较上一交易日上涨0.07%，近一年上涨23.82%。该公募基金现任基金经理为方伟。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020900020356.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","301293","BK1161","159938","BK0236","BK1515","BK1574"],"gpt_icon":0},{"id":"2610506629","title":"华昊中天医药-B：中国证监会就公司股份全流通发出备案通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2610506629","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610506629?lang=zh_cn&edition=full","pubTime":"2026-02-09 08:22","pubTimestamp":1770596520,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 华昊中天医药-B（02563）发布公告，本公司已接获中国证监会就申请于2026年2月5日发出的备案通知书。根据备案通知书，本公司已就实施H股全流通完成向中国证监会备案。备案通知书将自其发出日期起12个月内有效。本公司将向联交所申请转换及上市。\n 于本公告日期，转换及上市的实施计划详情尚未最终确定。本公司将根据上市规则及适用法律的规定于适当时候就转换及上市的进展及详情作出进一步公告。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-02-09/doc-inhmenrs2391138.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02563","BK1161","BK1515","09939","BK1574","159938"],"gpt_icon":0},{"id":"2609573727","title":"丹诺医药拿到IPO备案：暂无收入，9个月亏1.15亿 估值20亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2609573727","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609573727?lang=zh_cn&edition=full","pubTime":"2026-02-08 16:34","pubTimestamp":1770539667,"startTime":"0","endTime":"0","summary":"丹诺医药（苏州）股份有限公司（简称：“丹诺医药”）日前通过IPO备案，拿到了上市的钥匙。丹诺医药目前无收入，2025年前9个月亏损1.15亿。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260208/6390616523722649183398380.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260208/6390616523722649183398380.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n32610/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["BK1161","09939","BK1574","BK1515","159938"],"gpt_icon":0},{"id":"2609736518","title":"六大领域齐发力\n青海中（藏）医药为健康青海添动能","url":"https://stock-news.laohu8.com/highlight/detail?id=2609736518","media":"西海都市报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609736518?lang=zh_cn&edition=full","pubTime":"2026-02-07 01:13","pubTimestamp":1770397980,"startTime":"0","endTime":"0","summary":"青海省中医院、青海省藏医院与西宁14家社区卫生服务中心签约，推动优质资源下沉。此外，青海还广泛开展中（藏）医药文化传播活动，举办“从二十四节气走进青海传统中（藏）医药”系列活动，通过文化进校园、体验日等多种形式，增进群众对中（藏）医药文化的了解和认同。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-02-07/doc-inhkxipv4703989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","BK1515","159938","BK1161","BK1574"],"gpt_icon":0},{"id":"2609947255","title":"华昊中天医药-B(02563)：中国证监会就公司股份全流通发出备案通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2609947255","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609947255?lang=zh_cn&edition=full","pubTime":"2026-02-06 22:46","pubTimestamp":1770389214,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华昊中天医药-B(02563)发布公告，本公司已接获中国证监会就申请于2026年2月5日发出的备案通知书。根据备案通知书，本公司已就实施H股全流通完成向中国证监会备案。备案通知书将自其发出日期起12个月内有效。本公司将向联交所申请转换及上市。于本公告日期，转换及上市的实施计划详情尚未最终确定。本公司将根据上市规则及适用法律的规定于适当时候就转换及上市的进展及详情作出进一步公告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402818.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1515","BK1574","09939","BK1161","02563"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770908871998,"stockEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":-0.043},{"period":"3month","weight":-0.0566},{"period":"6month","weight":-0.0723},{"period":"1year","weight":0.1061},{"period":"ytd","weight":0.0277}],"compareEarnings":[{"period":"1week","weight":0.0073},{"period":"1month","weight":-0.008},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1177},{"period":"1year","weight":0.2453},{"period":"ytd","weight":0.0411}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"医药(159938)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供医药(159938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"医药,159938,医药股票,医药股票老虎,医药股票老虎国际,医药行情,医药股票行情,医药股价,医药股市,医药股票价格,医药股票交易,医药股票购买,医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"医药(159938)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供医药(159938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}